PPA
KLRS

Parametric Portfolio Associates’s Kalaris Therapeutics KLRS Stock Holding History

Parametric Portfolio Associates’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-543
Closed -$313K – 3707
2021
Q3 		$313K Sell
543
-18
-3% -$8.34K ﹤0.01% 3286
2021
Q2 		$255K Buy
+561
New +$290K ﹤0.01% 3318

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parametric Portfolio Associates's KLRS Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Kalaris Therapeutics (KLRS) in Q4 2021, closing a stake of 543 shares — an estimated $313K sold.

Parametric Portfolio Associates first reported a position in KLRS in Q2 2021 and held it in 2 quarters. The position peaked at $313K in Q3 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Kalaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 543 Kalaris Therapeutics shares in Q4 2021, an estimated $313K.
  • Parametric Portfolio Associates first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 2 quarters.
  • Parametric Portfolio Associates's Kalaris Therapeutics position peaked at $313K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.